Penetrium Bioscience KRX:187660KOSDAQ
현대ADM · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days11
DART filings, 7 days0
Articles tracked31since Sep 11
In Q2 2026, Penetrium Bioscience reported revenue of ₩2.1bn, down 16.2% year on year, and an operating loss of ₩1.9bn. Penetrium Bioscience (현대ADM) appeared in 11 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Nov 12 with 11 articles. The most common catalyst was clinical & approvals (1).
Filing signals Insider buying 4 quarters of losses Share pledge Screener
Penetrium Bioscience quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.1bn | -16.2% | −₩1.9bn margin −87.9% | −₩1.5bn |
| Q1 2026 | ₩1.7bn | -23.5% | −₩1.8bn margin −108.5% | −₩1.9bn |
| Q4 2025 derived | ₩1.9bn | -9.9% | −₩1.6bn margin −80.4% | −₩4.5bn |
| Q3 2025 | ₩2.6bn | +27.5% | −₩1.5bn margin −55.8% | −₩8.5bn |
| Q2 2025 | ₩2.5bn | -3.9% | −₩1.7bn margin −65.4% | ₩1.8bn |
| Q1 2025 | ₩2.2bn | -24.6% | −₩2.7bn margin −122.9% | −₩3.7bn |
| Q4 2024 derived | ₩2.1bn | -22.0% | −₩1.0bn margin −47.4% | −₩2.3bn |
| Q3 2024 | ₩2.0bn | -37.2% | −₩2.6bn margin −126.1% | −₩3.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Penetrium Bioscience top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Penetrium Bioscience news Korean headlines
-
PenitoPharma Bio presents fake resistance control research at American College of Rheumatology, expanding cancer combination strategy
1 more on this story · 1 outlets
- Penityrium Bio presents evidence of fake resistance control at ACR스페셜타임스 · Nov 12 23:59
-
Phaentrium Bio clarifies key mechanism at US conference reviving efficacy of overlooked anticancer drugs
1 more on this story · 1 outlets
-
Penitrium Bio presents non-resistance control evidence for Penitrium at US conference
1 more on this story · 1 outlets
- Penitrium Bio presents evidence of controlling 'fake resistance' at U.S. ACR머니투데이 · Nov 12 10:14
-
Global cancer experts see future in Penitrium Bio…U.S. phase 2a draws 'voluntary calls of support'
1 more on this story · 1 outlets